Rad51 and BRCA2 - New Molecular Targets for Sensitizing Glioma Cells to Alkylating Anticancer Drugs by Quiros, Steve et al.
Rad51 and BRCA2 - New Molecular Targets for
Sensitizing Glioma Cells to Alkylating Anticancer Drugs
Steve Quiros, Wynand Paul Roos, Bernd Kaina*
Institute for Toxicology, Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
Abstract
First line chemotherapeutics for brain tumors (malignant gliomas) are alkylating agents such as temozolomide and
nimustine. Despite growing knowledge of how these agents work, patients suffering from this malignancy still face a dismal
prognosis. Alkylating agents target DNA, forming the killing lesion O
6-alkylguanine, which is converted into DNA double-
strand breaks (DSBs) that trigger apoptosis. Here we assessed whether inhibiting repair of DSBs by homologous
recombination (HR) or non-homologous end joining (NHEJ) is a reasonable strategy for sensitizing glioma cells to alkylating
agents. For down-regulation of HR in glioma cells, we used an interference RNA (iRNA) approach targeting Rad51 and
BRCA2, and for NHEJ we employed the DNA-PK inhibitor NU7026. We also assessed whether inhibition of
poly(ADP)ribosyltransferase (PARP) by olaparib would enhance the killing effect. The data show that knockdown of
Rad51 or BRCA2 greatly sensitizes cells to DSBs and the induction of cell death following temozolomide and nimustine
(ACNU). It did not sensitize to ionizing radiation (IR). The expression of O
6-methylguanine-DNA methyltransferase (MGMT)
abolished all these effects, indicating that O
6-alkylguanine induced by these drugs is the primary lesion responsible for the
formation of DSBs and increased sensitivity of glioma cells following knockdown of Rad51 and BRCA2. Inhibition of DNA-PK
only slightly sensitized to temozolomide whereas a significant effect was observed with IR. A triple strategy including siRNA
and the PARP inhibitor olaparib further improved the killing effect of temozolomide. The data provides evidence that down-
regulation of Rad51 or BRCA2 is a reasonable strategy for sensitizing glioma cells to killing by O
6-alkylating anti-cancer
drugs. The data also provide proof of principle that a triple strategy involving down-regulation of HR, PARP inhibition and
MGMT depletion may greatly enhance the therapeutic effect of temozolomide.
Citation: Quiros S, Roos WP, Kaina B (2011) Rad51 and BRCA2 - New Molecular Targets for Sensitizing Glioma Cells to Alkylating Anticancer Drugs. PLoS ONE 6(11):
e27183. doi:10.1371/journal.pone.0027183
Editor: David L. McCormick, IIT Research Institute, United States of America
Received July 19, 2011; Accepted October 11, 2011; Published November 2, 2011
Copyright:  2011 Quiros et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The Deutsche Forschungsgemeinschaft and German Cancer Research Fund supported this work. SQ was supported by the Deutscher Akademischer
Austauschdienst (grant A/06/05736). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kaina@uni-mainz.de
Introduction
Glioblastoma multiforme (GBM, WHO grade IV) is the
deadliest form of malignant brain tumors. Complete surgical
resection of this tumor is hampered by its inherent invasiveness
into the surrounding healthy brain tissue. As the tumor cannot be
removed completely, adjuvant chemo-radiotherapy plays a major
role in the treatment of patients. Nevertheless, despite the best
available therapeutic approach, the survival rate for patients with
this malignancy is below 1.5 years after diagnosis [1]. Temozo-
lomide (TMZ) is the current first-line chemotherapeutic for
gliomas. Similar to other methylating chemotherapeutics such as
procarbazine, dacarbazine and streptozotocine, TMZ-induced
cell-kill is mainly due to O
6-methylguanine (O
6MeG), which is a
minor lesion induced by these agents in DNA. The suicide enzyme
O
6-methylguanine-DNA methyltransferase (MGMT) repairs
O
6MeG and thereby renders cells resistant to methylating agents
[2]. Consequently, MGMT activity and the promoter methylation
status of the MGMT gene (indicators of O
6MeG repair capacity
and MGMT protein expression, respectively) are used as
predictive markers for the response of gliomas to TMZ [3,4]. As
a result of the protective role of MGMT in methylating and
chloroethylating agent based therapy, MGMT inhibitors are in
trials for use in MGMT expressing tumors [5].
O
6MeG is processed into DNA double-strand breaks (DSBs) in
a DNA mismatch repair (MMR)-dependent manner, which
requires two rounds of DNA replication [6,7,8,9]. These DSBs
then trigger apoptotic cell death in gliomas [10]. For chloroethy-
lating agents such as nimustine (ACNU), O6-chloroethylguanine
forms secondary interstrand crosslinks that in turn give rise to
DSBs (for review see [2]). Cells can protect against DSBs via two
repair pathways, namely non-homologous end joining (NHEJ) and
homologous recombination (HR).
NHEJ is a error-prone process that relies on the coordinated
action of Ku70/Ku80, DNA-PKcs, Artemis, XRCC4 and DNA
ligase IV, among other factors, to rejoin the two ends of a broken
DNA molecule [11,12]. HR employs sequence homology to
perform an error-free break correction that preserves the original
DNA sequence. The central reaction of the HR pathway, namely
the homology search and strand invasion, is performed by Rad51-
coated 39- single stranded DNA (ssDNA) tails generated by DNA
end resection of the break [13,14]. The formation of this
nucleoprotein filament at ssDNA is promoted and stabilized by
BRCA2 [15,16]. Both Rad51 and BRCA2 are essential for HR in
mammalian cells. A significant function of Rad51 and BRCA2 in
other repair pathways has not been described.
Working with rodent cells mutated in these DSB repair
pathways, we were able to show that HR, but not NHEJ, is
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27183responsible for resistance to DSBs formed in response to TMZ-
induced O
6MeG [17]. Similar data were obtained for cells treated
with chloroethylating agents like ACNU and lomustine (CCNU),
which are also used in glioma therapy (Nikolova et al.,
unpublished data). These findings suggest that HR might be a
promising target in methylating and chloroethylating agent based
glioma therapy.
This work was aimed at assessing whether knockdown of HR in
glioma cells by interference RNA (iRNA) leads to improved killing
of glioma cells following treatment with TMZ, ACNU and
ionizing radiation (IR), all part of the standard care for patients
with this malignancy.
Results and Discussion
Knockdown of the homologous recombination proteins
Rad51 and BRCA2 sensitizes glioma cells to alkylating
anti-cancer drugs
O
6-alkylating agents (O
6AA) are widely used as standalone
agents or as part of regimes for the treatment of glioma, malignant
melanoma, Hodgkin’s and non-Hodgkin lymphoma, sarcoma and
islet cell carcinoma of the pancreas. To determine whether down-
regulation of HR would lead to increased sensitivity of glioma cells
to O
6AA, stable and transient iRNA transfections targeting HR
proteins were performed in these cells. LN-229 glioma cells stably
knocked-down for Rad51 (Fig. 1A demonstrating parental cells
and four stable Rad51sh transfectants), which is the protein
responsible for homology search and strand invasion, showed a
profound increase in both TMZ (Fig. 1B) and ACNU (Fig. 1C)
induced cell death. Remarkably, this increase in sensitivity was
proportional to the increase in Rad51 knockdown (Fig. 1D; a
similar quantitative correlation was found for ACNU (not shown)).
One may suppose that knockdown of Rad51 causes a general
sensitization that pertains to all genotoxins including IR. To
determine whether this is the case, LN-229 Rad51 knockdown
cells were exposed to increasing doses of c-radiation, which
contrary to O
6AA induce DSBs directly. A slight increase in
sensitivity in the Rad51 knockdown lines compared to the control
line was observed (Fig. 1E), although not as dramatic as the
sensitization towards O
6AA (compare with Fig. 1B and 1C).
To determine whether the sensitization of glioma cells to O
6AA
chemotherapeutics is not exclusive for Rad51 knockdown,
BRCA2, the scaffold protein that promotes and stabilizes the
presynaptic filament formation during HR repair, was transiently
down-regulated (Fig. 2A). Similar to Rad51, BRCA2 knockdown
also caused sensitization of glioma cells to TMZ and ACNU
(Fig. 2B and 2C). Again, for ionizing radiation the increase in cell
kill after BRCA2 knockdown was less prominent (Fig. 2D). These
results suggest that HR plays a protective role in glioma cells
treated with TMZ or ACNU and that saturation of HR must
occur before O
6AA chemotherapeutics trigger cell death.
Cell death in stable Rad51 down-regulated cells showed a
strong increase in apoptosis following TMZ treatment compared
to control as determined by annexin V/PI flow cytometry (Fig. 3A).
This is in line with previous data obtained with glioma cells
showing that apoptosis is the major cell death pathway following
TMZ [10]. If Rad51 represents a general mechanism for TMZ
resistance in glioma cells, then knockdown of Rad51 in other
glioma cells should also lead to increased sensitivity towards TMZ
triggered apoptosis. To prove this, Rad51 was transiently knocked-
down in the glioma cell lines U87MG and T98G (Fig. 3B). TMZ
induced apoptosis was determined in these cells and compared to
the response of LN-229 cells transfected with the pS-empty and
Rad51sh vector (Fig. 3C). We should note that for the cell line
T98G, MGMT was depleted by O
6BG, while LN-229 and
U87MG does not express MGMT and therefore O
6BG
pretreatment was not necessary. All three cell lines showed a
significant increase in TMZ triggered apoptosis following Rad51
knockdown (Fig. 3C). These results support the view that the
chemo-sensitizing effect of HR down-regulation is a general
phenomenon that is not restricted to a particular glioma cell line.
Sensitization of Rad51 knockdown depends on O
6-
alkylguanine lesions
TMZ methylates DNA at 13 positions [18]. Prominent
alkylation lesions are N7-methylguanine, N3-methyladenine, N3-
methylguanine and O
6-methylguanine. In rodent cells, HR has
been reported to be the major downstream protection mechanism
against both N-alkylations in purines [19] and O
6-alkylations in
guanine [17]. The TMZ-induced adduct O
6MeG is repaired by
MGMT [2]; consequently, over-expression of MGMT in HR
knockdown glioma cells should render them resistant to TMZ if
HR knockdown sensitizes towards the O
6MeG adduct. LN-229
does not express MGMT detectably. Therefore, we transfected
MGMT into these cells generating stable MGMT transfectants
(Fig. 4A). As expected, these cells were highly protected against
TMZ-induced cell death. Knockdown of Rad51 in these cells had
no significant effect on TMZ-induced toxicity (Fig. 4B, compare
with Fig. 1B). The data shows that blocking the HR repair
pathway by Rad51 knockdown sensitizes to cell death triggered by
the DNA adduct O
6MeG.
Although brain tumors usually express low levels of MGMT
[20], a major fraction of these malignancies do indeed show
clinically relevant expression levels of this repair enzyme, making
them unsuitable for treatment with O
6AA. To overcome this
problem, MGMT inhibitors are being tested in trials for
enhancing the effectiveness of TMZ and related agents. Employ-
ing a model that resembles this situation, T98G glioma cells that
express endogenous MGMT were knocked-down for Rad51. The
MGMT expressing T98G cells were completely resistant to TMZ,
irrespective of Rad51 knockdown (Fig. 4C). This data are similar
to those obtained with LN-229 MGMT transfected cells,
supporting the notion that HR knockdown sensitizes glioma cells
to O
6MeG adducts and that MGMT inhibition greatly improves
on this.
Knockdown of Rad51 in glioma cells prevents the repair
of DSBs formed during the processing of O
6-
methylguanine
Having shown that knockdown of HR proteins sensitizes glioma
cells to O
6AAs, the question of whether it would also have an effect
on the formation and repair of DSBs following TMZ treatment
was addressed. A reliable and robust marker for DSBs are
phosphorylated histone 2AX (cH2AX) foci [21]. Glioma cells
knocked-down in Rad51 were treated with TMZ and compared
with non-knockdown cells as to DSB formation and repair (Fig. 5A
for representative immunofluorescence and Fig. 5B for quantifi-
cation). In control cells transfected with the empty vector, DSBs
were formed 48 h after treatment and then repaired (Fig. 5B),
which conforms to previous data [17]. Contrary to this, in Rad51
knockdown lines (clones 8 and 23) DSBs were formed and
remained unrepaired up to 144 h after TMZ treatment (Fig. 5B).
Clearly, knockdown of Rad51 in glioma cells caused a significant
defect in the repair of DSBs induced by TMZ. The inhibition of
DSB repair as determined by cH2AX showed an inverse and
significant correlation with Rad51 expression in the knockdown
cells (Fig. 6A). The cH2AX foci level that remained after 144 h
Homologous Recombination and Chemo-Sensitization
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6AA chemotherapeutics. (A) Rad51 protein expression in
knockdown clones and control assessed by western blot, quantified, corrected for loading (Erk-2) and expressed relative to control. (B) Clonogenic
survival for stable Rad51 knockdown glioma cells (LN229-Rad51sh) compared to empty vector transfected cells (LN-229-pS-empty) following TMZ
treatment. (C) Clonogenic survival for stable Rad51 knockdown glioma cells compared to empty vector transfected cells following ACNU treatment.
(D) Correlation between the relative Rad51 expression, determined from A, and TMZ concentration that kills 95% of glioma cells, determined from B.
Line was fitted using the equation y=minimum + (maximum-minimum)6(1-exp(-kx)). (E) Clonogenic survival for stable Rad51 knockdown glioma
cells compared to empty vector transfected cells following ionizing radiation (IR).
doi:10.1371/journal.pone.0027183.g001
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confirm that TMZ-induced cH2AX foci are ‘‘true’’ DSBs, a
second DSB marker was used that is known to physically interact
with cH2AX, namely 53BP1 [22]. Similar to cH2AX, TMZ also
induced the formation of 53BP1 foci, which co-localized with
cH2AX (Fig. 7). The data support the notion that Rad51
dependent HR is required for the repair of TMZ-induced DSBs.
Influence of inhibiting NHEJ or poly(ADP-
ribose)polymerase on TMZ treated glioma cells
As NHEJ may theoretically also play a protective role for
methylating agents, independent of HR, its effect was investigated
in TMZ-treated glioma cells. A main player in NHEJ is DNA-
PKcs, which is a PI3-kinase that binds, together with Ku70 and
Ku80, to free DSB ends and stimulates their rejoining and ligation
[11,12]. For inhibiting DNA-PK we used the small molecule
inhibitor NU7026 [23], which strongly inhibited DNA-PK activity
upon treatment of both LN-229 control (transfected with the
empty vector) and LN-229 Rad51 transfected cells (Fig. 8A).
Inhibition of DNA-PK with NU7026 in LN-229 cells treated with
TMZ, irrespective of Rad51 knockdown, had no significant effect
on survival (Fig. 8B), indicating that NHEJ does not protect
significantly against TMZ. This is in line with our previous data
obtained with rodent mutant cells, which showed that NHEJ only
contribute marginally to the protection against O
6-methylating
agents [17]. Interestingly, DNA-PK inhibition had a significant
sensitization effect on LN-229 glioma cells treated with c-rays
(Fig. 8B), which supports the observation that NHEJ was indeed
inhibited in these cells. The results suggest a divergent role for this
pathway in the repair of TMZ and ionizing radiation-induced
DNA damage.
Synthetic lethality caused by PARP inhibitors in HR-deficient
cells [24] has paved the way for several clinical trials for the use of
these inhibitors in HR-deficient tumors. This prompted us to study
the effect of PARP inhibition on Rad51 knockdown cells. As
shown in Fig. 8C, PARP inhibition with olaparib resulted in
Figure 2. Knockdown of the HR protein BRCA2 sensitizes glioma cells to O
6AA chemotherapeutics. (A) BRCA2 protein expression
following knockdown was assessed by western blot. (B) Clonogenic survival following TMZ treatments in transient BRCA2 or non-sense (n.s.) siRNA
transfected glioma cells. (C) Clonogenic survival following ACNU treatments in transient BRCA2 or non-sense (n.s.) siRNA transfected glioma cells. (D)
Clonogenic survival following ionizing radiation (IR) in transient BRCA2 or non-sense (n.s.) siRNA transfected glioma cells.
doi:10.1371/journal.pone.0027183.g002
Homologous Recombination and Chemo-Sensitization
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27183increased killing in glioma cells knocked-down for Rad51
compared to controls. Co-treatment with TMZ and olaparib
increased cell kill in both control and knocked-down cells; the most
drastic decrease in survival was observed in the latter. The data
indicates that glioma cells are unable to deal with TMZ-induced
DNA damage when PARP is inhibited, which is exacerbated when
HR is down-regulated by Rad51 knockdown.
Outlook
Collectively, the data shows a dramatic increase in the
sensitivity of glioma cells treated with O
6-methylating (TMZ)
and O
6-chlorethylating (ACNU) anticancer drugs once HR was
impaired by knockdown of its major players Rad51 and BRCA2.
This was demonstrated in glioma cell lines proficient (LN-229 and
U87MG) and deficient (T98G) for p53. Although MGMT
Figure 3. Apoptosis induction after TMZ treatment in Rad51 kd glioma cells. (A) Apoptosis determined by annexin V/PI double-staining
144 h after 10 mM TMZ in stable Rad51 knockdown clones of the cell line LN229. (B) Western blot analysis of transient Rad51 knockdown in U87MG
and T98G cells, or transfected with non-sense siRNA. Erk-2 was used as loading control. (C) Apoptosis induction after TMZ treatment in Rad51
transient knocked-down glioma cells U87MG and T98G, as well as in the stable Rad51 knockdown clone LN-229-Rad51-sh8 and the empty vector
control cell line LN-229-pS-empty. Apoptosis was assessed by Sub-G1 analysis performed 144 h after 10 mM TMZ treatment. For MGMT depletion
10 mMO
6BG was added 1 h before TMZ. * p,0.05, significance level determined using the t-student test (n=3).
doi:10.1371/journal.pone.0027183.g003
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knockdown, its pharmacological inhibition by the pseudosubstrate
O
6BG restored it. The data also corroborates previous observa-
tions indicating a minor role of NHEJ in the repair of O
6MeG
triggered DSBs [17], and indicates a potential use of PARP
inhibitors to further enhance TMZ-induced toxicity in glioma
cells. As O
6AA are employed so widely as part of the treatment of
different tumors, especially in the metastatic state and when
complete surgical removal of the neoplasm is not possible,
enhancement of chemotherapy efficacy is highly desired.
While we demonstrated that down-regulation of Rad51 and
BRCA2 greatly sensitizes glioma cells to TMZ and ACNU and,
therefore, are potential new targets in glioma therapy, the
limitation of this approach should also be pondered. High
MGMT levels still provoke resistance and therefore tumors
with an unfavorable MGMT status will still represent a major
hurdle. We should note, however, that HR also protects
against N-alkylations (Nikolova et al., in preparation), which
are formed by TMZ and CNUs at high amounts and are
repaired by base excision repair. It is thus conceivable that
inhibition of repair of N-alkylations together with knockdown of
HR might be a strategy for targeting tumors that express high
MGMT levels.
Another important issue pertains to the tumor targeting for HR
knockdown strategies, in order to prevent unwanted side effects
due to enhanced normal tissue toxicity. Indeed, systemic down-
regulation of HR might exacerbate the side effects related to
chemotherapeutics. Therefore, either local administration directly
to the tumor or a proper tumor targeting strategy for iRNA
[25,26] and MGMT inhibitors [5,27] might be fundamental for
optimizing the therapeutic index of this approach. In summary,
the study provides proof of principle evidence that siRNA
targeting the HR pathway is a reasonable strategy for increasing
O
6AA efficacy, which may prove beneficial for patients treated
with these anticancer drugs.
Materials and Methods
Cell lines and culture conditions
LN-229, U87MG and T98G cells were provided by Dr. M.
Weller (Department of Oncology, University Hospital Zurich,
Switzerland) [28] and were checked before experimental use for
mycoplasma contamination. Cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal bovine
serum as previously described [29,30]. Cells were cultured in a
humidified atmosphere with 7% CO2 at 37uC.
Drugs, treatments and irradiation of cells
TMZ (a generous gift from Schering-Plough) stocks were
prepared by dissolving it in DMSO and sterile dH2O (1:2) to a
concentration of 35 mM. ACNU (Sigma) stocks were prepared by
dissolving it in sterile dH2O to 10 mM. O
6-benzylguanine (O
6BG,
Sigma), NU7026 (Sigma) and Olaparib (AZD2281, Selleck
Chemicals) stocks were prepared by dissolving them in DMSO
to 10 mM, 5 mM and 10 mM, respectively. TMZ stocks were
stored at 280uC while the other stocks were stored at 220uC. For
MGMT depletion or PARP inhibition, O
6BG (10 mM) or
Olaparib was added 1 h prior to drug treatments. NU7026
(10 mM) was added to cells 6h prior to treatments. Radiation was
performed with a
137Cs source (Gammacell 2000, Molsgaard
Medical).
Plasmids and stable transfections
A pSuper (OligoEngine) construct was generated to express
shRNA targeting Rad51 mRNA using the previously described
sequence (59- GAAGAAAUUGGAAGAAGCU-39) [31]. The
pSV2MGMT vector has been described previously [32]. Plasmid
DNA were transfected using Effectene (Qiagen). Transfected cells
were selected with 0.75 mg/ml G418 or 0.44 mg/ml puromycin
(both from Invitrogen) until clones formed.
Transient transfection
BRCA2 siRNA (59-CUGAGCAAGCCUCAGUCAAtt-39),
Rad51 siRNA (5 `-GAAGAAAUUGGAAGAAGCUtt-39), (target
Figure 4. HR downregulation sensitizes to O
6-alkylguanine
lesions in glioma cells. (A) Western blot analysis of MGMT and
Rad51 protein levels of glioma cells stably transfected to express
MGMT (LN-229-MGMT) and cells stably expressing MGMT and
knockdown for Rad51 (LN-229-MGMT+Rad51sh). Erk-2 was used for
loading control. (B) Clonogenic survival for cells stably transfected to
express MGMT (LN-229-MGMT) and cells stably expressing MGMT and
knockdown for Rad51 (LN-229-MGMT+Rad51sh) after TMZ treatment.
(C) Apoptosis in T98G glioma cells that were transiently knocked-down
for Rad51 (or transfected with non-sense siRNA) treated with TMZ.
Apoptosis was determined by Sub-G1 flow cytometry 144 h after TMZ
addition.
doi:10.1371/journal.pone.0027183.g004
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27183Figure 5. HR down-regulation impairs the repair of TMZ induced DNA-DSBs. Kinetics of TMZ-induced cH2AX foci formation and
disappearance in Rad51 knockdown glioma cells treated with 10 mM TMZ. See (A) for representative micrographs and (B) for quantification. Each
measure point represents the mean of 200 cells per experiment. Experiments were repeated twice and mean values +/2 SD are shown.
doi:10.1371/journal.pone.0027183.g005
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non-sense siRNA (AllStars Negative Control siRNA, Qiagen) were
transfected with Lipofectamine RNAiMAX (Invitrogen).
Flow cytometric analysis
For Sub-G1 analysis, harvested cells were fixed in 70% ethanol
at -20uC. RNA digested-cells (30 mg/ml RNase A for 1 h in PBS)
were stained with 16.7 mg/ml propidium iodide (PI) prior to FACS
analysis. Annexin V-FITC/ PI double-staining was performed
following the manufacturer specifications (BD Pharmingen). Flow
cytometry analysis was performed using a FACSCalibur (Becton
Dickinson).
Colony Formation Assay
Cells in logarithmic growth were seeded at appropriate numbers
on 60 mm dishes. Cells were allowed to attach for 6 h before
irradiation or drug treatments. Colonies were fixed in acetic
acid:methanol:H2O (1:1:8), and stained with 1.25% Giemsa and
0.125% violet crystal. Transient transfected cells were seeded on
dishes 18 h after transfection.
Immunofluorescence microscopy
Cells were sequentially fixed with 4% formaldehyde and 100%
methanol. Primary antibodies (anti-phospho-S139-H2AX, 1:1000,
Upstate; anti-53BP1, 1:400, Cell Signaling) were incubated
Figure 6. Correlations between Rad51 expression level and cH2AX foci (A) and the amount of cH2AX foci and cell death (B). Relative
Rad51 expression was determined from Fig.1A and the doses required to kill 95% of glioma Rad51 knockdown cell lines cells are from Fig.1B.
doi:10.1371/journal.pone.0027183.g006
Figure 7. Co-localization of 53BP1 and cH2AX. 53BP1 was immuno-detected as a second marker for DSB. Representative micrographs are
shown.
doi:10.1371/journal.pone.0027183.g007
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antibody (anti mouse- Alexa Fluor 488, 1:500, Invitrogen; anti-
rabbit-Cy
TM3, 1:500, Jackson ImmunoResearch Laboratories).
DNA was counterstained either with 100 nM DAPI or 1 mM TO-
PRO-3 (Invitrogen). Slides were mounted in 1% DABCO- 50%
glycerol- PBS. Foci were scored automatically with the Metafer
Finder System v.3.1 (MetaSystems). Microphotographs were
acquired by laser scanning microscopy (LSM710, Carl Zeiss
MicroImaging).
DNA-PK activity assay
Total cell extracts were prepared as described [34]. Briefly,
cells were lysed using three cycleso ff r e e z e( l i q u i dn i t r o g e n ) /
thaw (30uC) in extraction buffer (50 mM NaF, 20 mM HEPES
(pH 7.8), 450 mM NaCl, 25% glycerol, 0.2 mM EDTA,
0.5 mM dithiothreitol, in the presence of protease inhibitors
(Complete. EDTA-free. Roche)). Extracts were centrifuged (12
0 0 0r p m f o r 3 0m i n a t 4 uC), and supernatants were shock
frozen and stored at 280uC. Endogenous DNA was removed
by DEAE Sepharose Fast Flow (GE Healthcare). DNA-PK
activity was determined by liquid scintillation counting using the
SignaTECT DNA-Dependent Protein Kinase Assay System
(Promega). The assay was performed on three independent
cell extracts for each cell line. Each sample was analyzed in
the presence or absence of 10 mM of the DNA-PKcs inhi-
bitor NU7026. For background control, reactions were per-
formed in the absence of activator, as suggested by the assay
manufacturer.
Western blot analysis
Samples were resolved by SDS-PAGE, and blotted onto a
nitrocellulose membrane. Primary antibodies [BRCA2 (Cell
Signaling), Erk-2 (Santa Cruz), MGMT (Millipore), Rad51
(Calbiochem)] were used and detected by the OdysseyH Infrared
Imaging System (LI-COR Biotechnology).
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Figure 8. Role of DNA-PK dependent NHEJ and PARP
dependent BER on sensitivity of glioma cells knockdown
for Rad51 towards TMZ. (A) Inhibition of DNA-PK activity with
NU7026. DNA-PK activity was dete r m i n e di nc e l le x t r a c t si nt h e
presence and absence of NU7026. (B) Clonogenic survival of
stable Rad51 knocked-down glioma cells (LN-229-Rad51sh-4)
compared to empty vector-transfected cells (LN-229-pS-empty) after
TMZ or ionizing radiation (IR) treatment in the presence or absence
of the DNA-PKcs inhibitor NU7026. Equitoxic TMZ and ionizing
radiation (IR) doses producing about 30 to 40% toxicity in the
absence of DNA-PK inhibition were used [TMZ/IR doses: LN-229-pS-
empty: 2.7 mM/2.7Gy; LN-229-Rad51sh-4: 1.5 mM / 1 . 9G y ] .* ,p ,0.05,
significance levels were calculated using the Mann-Whitney U test
(n=5). (C) Clonogenic survival of control (LN-229-pS-empty-2) and
Rad51 knockdown (LN-229-Rad51sh-23) glioma cells as a function of
olaparib concentration. Cells were co-treated with TMZ or not. TMZ
doses producing 30 to 40% toxicity in the absence of PARP inhibition
were selected for LN-229-Rad51sh-23 (0.8 mM) and control cells
(2.5 mM).
doi:10.1371/journal.pone.0027183.g008
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